Get started
Award

MC_PC_19056

Funded outputs count: 41
Funder award ID: MC_PC_19056
OpenAlex ID: G8381483046
Long-term follow-up of treatment comparisons in RECOVERY: a randomised, open-label, platform trial for patients hospitalised with COVID-19
2025 · Peter W Horby, Leon Peto, et al. · medRxiv
PDF
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases
PDF
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · Syed Zaigham Ali Shah · 1
PDF
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12
PDF
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O. Abani, A. Abbas, et al. · EClinicalMedicine · 5
Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
2025 · Peter W Horby, Jonathan R Emberson, et al. · medRxiv · 2
PDF
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
2024 · Shankar-Hari M, Murthy S, et al. · Carolina Digital Repository (University of North Carolina at Chapel Hill)
PDF
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2024 · RECOVERY Collaborative Group, Peter W Horby, et al. · medRxiv · 1
PDF
Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England
2024 · Guilherme Pessoa-Amorim, Raphael Goldacre, et al. · Trials · 4
PDF
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2024 · RECOVERY Collaborative Group, Peter Sandercock, et al. · Nature Communications · 11
PDF
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39
PDF
Correction to Lancet Diabetes Endocrinol 2023; 11: 905–14
2023 · The Lancet Diabetes & Endocrinology
PDF
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41
PDF
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · Peter W Horby, Natalie Staplin, et al. · medRxiv · 5
PDF
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129
Higher dose corticosteroids in hospitalised COVID-19 patients with hypoxia but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2022 · RECOVERY Collaborative Group, Peter W Horby, et al. · medRxiv · 5
PDF
Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19
2022 · Peter A. G. Sandercock, Janet Darbyshire, et al. · Trials · 7
PDF
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2022 · RECOVERY Collaborative Group, Peter W Horby, et al. · medRxiv · 2
PDF
AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021–2022
2022 · Jennifer M Grant, Justin Chan, et al. · Journal of the Association of Medical Microbiology and Infectious Disease Canada · 2
PDF
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022 · RECOVERY Collaborative Group, Peter W Horby, et al. · medRxiv · 46
PDF
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · RECOVERY Collaborative Group, Peter W Horby, et al. · The Lancet Respiratory Medicine · 211
PDF
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · RECOVERY Collaborative Group, Peter W Horby, et al. · medRxiv · 143
PDF
Year
Topic